Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 6
2012 10
2013 7
2014 4
2015 3
2016 6
2017 5
2018 4
2019 3
2020 8
2021 7
2022 8
2023 7
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzis MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. Janjigian YY, et al. Among authors: tehfe m. Lancet. 2021 Jul 3;398(10294):27-40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5. Lancet. 2021. PMID: 34102137 Free PMC article. Clinical Trial.
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, Shitara K. Janjigian YY, et al. Among authors: tehfe m. J Clin Oncol. 2024 Jun 10;42(17):2012-2020. doi: 10.1200/JCO.23.01601. Epub 2024 Feb 21. J Clin Oncol. 2024. PMID: 38382001 Free PMC article. Clinical Trial.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Shitara K, et al. Among authors: tehfe m. Nature. 2022 Mar;603(7903):942-948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23. Nature. 2022. PMID: 35322232 Free PMC article. Clinical Trial.
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators. Tempero MA, et al. J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521097 Free PMC article. Clinical Trial.
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Fuchs CS, et al. Among authors: tehfe m. Lancet. 2014 Jan 4;383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3. Lancet. 2014. PMID: 24094768 Clinical Trial.
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial.
Knox JJ, Jang GH, Grant RC, Zhang A, Ma L, Elimova E, Jang R, Moore M, Biagi J, Tehfe M, Ramjeesingh R, Tsang ES, Holter S, Ramotar S, Hutchinson S, Liang SB, Lungu IM, Moura S, Wang Y, Perera S, Chan-Seng-Yue M, Monajemzadeh M, Aung K, Prince R, Romero JM, Fuentes-Antras J, Gonzalez Conchas GA, Picardo S, Gonzalez R, Ghai S, Khalili K, Kyoung Kim T, Ng K, Bartlett J, Pugh TJ, Kalimuthu SN, Fischer SE, Wilson JM, Dodd A, Zogopoulos G, Grünwald BT, Notta F, Gallinger S, O'Kane GM. Knox JJ, et al. Among authors: tehfe m. Nat Commun. 2025 Jul 1;16(1):5919. doi: 10.1038/s41467-025-60808-z. Nat Commun. 2025. PMID: 40593593 Free PMC article.
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative.
Terry Fox Research Institute Marathon of Hope Cancer Centers Network. Electronic address: mmarra@bcgsc.ca; Terry Fox Research Institute Marathon of Hope Cancer Centers Network. Terry Fox Research Institute Marathon of Hope Cancer Centers Network. Electronic address: mmarra@bcgsc.ca, et al. Cancer Cell. 2025 Apr 14;43(4):587-592. doi: 10.1016/j.ccell.2025.03.014. Epub 2025 Apr 3. Cancer Cell. 2025. PMID: 40185094 Review.
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
Renouf DJ, Loree JM, Knox JJ, Topham JT, Kavan P, Jonker D, Welch S, Couture F, Lemay F, Tehfe M, Harb M, Aucoin N, Ko YJ, Tang PA, Ramjeesingh R, Meyers BM, Kim CA, Du P, Jia S, Schaeffer DF, Gill S, Tu D, O'Callaghan CJ. Renouf DJ, et al. Among authors: tehfe m. Nat Commun. 2022 Aug 26;13(1):5020. doi: 10.1038/s41467-022-32591-8. Nat Commun. 2022. PMID: 36028483 Free PMC article. Clinical Trial.
Canadian Surgery Forum.
Fayez R, Roy M, Villeneuve S, AlMuntashery A, Demyttenaere S, Christou N, Court O, AlMuntashery A, Fayez R, Demyttenaere S, Christou N, Court O, Bodie G, Bonrath E, Hagen J, Okrainec A, Sullivan P, Grantcharov T, Almamar A, Sharma A, Karmali S, Birch DW, Gill RS, Majumdar SR, Wang X, Tuepah R, Klarenbach SW, Birch DW, Karmali S, Sharma AM, Padwal RJ, Raîche I, Smith C, Haggar F, Moloo H, Poulin EC, Martel G, Yelle JD, Mamazza J, Mueller CL, Jackson TD, Penner T, Pitzul K, Urbach DR, Okrainec A, AlMuntashery A, Villeneuve S, Roy M, Fayez R, Demyttenaere S, Christou N, Court O, Fayez R, Roy M, Villeneuve S, AlMuntashery A, Demyttenaere S, Christou N, Court O, AlMuntashery A, Fayez R, Demyttenaere S, Court O, Christou N, Moustarah F, Biertho L, Hould FS, Lebel S, Lescelleur O, Marceau S, Marceau P, Biron S, Khokhotva M, Grantcharov T, Anvari M, Sharma A, Yusuf S, Kwong J, Okrainec A, Pitzul KB, Urbach DR, Jackson T, Elkassem S, Lindsay D, Sullivan P, Smith L, Bonrath E, Zevin B, Dedy N, Grantcharov TP, Zevin B, Bonrath EM, Aggarwal R, Grantcharov T, Sockalingam S, Cassin S, Crawford S, Pitzul K, Khan A, Hawa R, Jackson T, Okrainec A, Smith C, Brar B, Mamazza J, Raîche I, Yelle JD, Ha… See abstract for full author list ➔ Fayez R, et al. Among authors: tehfe m. Can J Surg. 2012 Aug;55(4 Suppl 1):S63-S135. doi: 10.1503/cjs.016712. Can J Surg. 2012. PMID: 35488395 Free PMC article. No abstract available.
Metastatic gastric cancer treatment: Second line and beyond.
Ghosn M, Tabchi S, Kourie HR, Tehfe M. Ghosn M, et al. Among authors: tehfe m. World J Gastroenterol. 2016 Mar 21;22(11):3069-77. doi: 10.3748/wjg.v22.i11.3069. World J Gastroenterol. 2016. PMID: 27003986 Free PMC article. Review.
81 results